Pharma Pulse: AstraZeneca’s US Setback and Europe’s Medicine Marathon

Feb 04, 10:30 AM

Headliner
Share
Subscribe
In today’s Pharma Pulse, AstraZeneca faces a complete response letter for its self-injectable lupus drug, while the EMA gives the green light to a historic wave of new therapies for MASH, rare diseases, and postmenopause.
Share
Subscribe
Next
Pharma Pulse: Transparency Mandates and the Novartis Patent Storm
Top episodes
Incorporating AI into Commercialization Plans
by Pharmaceutical Commerce
Overcoming Supply Chain Challenges
by Pharmaceutical Commerce
The Capabilities of a 3PL Provider
by Pharmaceutical Commerce